Bluebird Bio is splitting into two companies, one focused on rare diseases and the other on cancer drugs, according to the Wall Street Journal.
Bluebird Bio is splitting into two companies, one focused on rare diseases and the other on cancer drugs, according to the Wall Street Journal.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.